华熙生物去年净利润高增，销售费用同比降逾30%

Core Viewpoint - Huaxi Biological expects a significant increase in net profit for 2025, driven by systematic transformation rather than short-term scale expansion [1][3] Financial Performance - The company anticipates a net profit attributable to shareholders of between 270 million to 320 million yuan, representing a year-on-year growth of 54.93% to 83.63% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 167 million to 217 million yuan, with a year-on-year increase of 55.68% to 102.29% [1] Cost Management - Sales expenses are expected to decrease by over 30% in 2025 [3] - Management expenses are projected to decline by more than 10% year-on-year [3] Strategic Transformation - The company is transitioning from a scale-oriented approach to a quality and efficiency-oriented strategy, leading to a deep restructuring of its operational model [3] - Organizational management has been optimized by integrating overlapping functions and promoting a flatter, more agile structure to enhance decision-making efficiency [3] Research and Development - Huaxi Biological focuses on the key role of carbohydrates in cell differentiation and signaling mechanisms, with research centered on three core areas: extracellular matrix, intercellular communication, and intracellular processes [3] - The company is advancing original technology layouts and product transformations in the areas of aging intervention and tissue regeneration [3] AI Integration - The company is actively promoting the deep integration of AI with business scenarios, enhancing smart upgrades in R&D, manufacturing, supply chain management, and financial operations [3]